Arsenic Trioxide: Pharmacological Applications

Q3 Pharmacology, Toxicology and Pharmaceutics

Vitae Pub Date : 2023-04-20 DOI:10.17533/udea.vitae.v30n1a349001

German Madrigal Redondo, M. F. Rojas Salas, Rolando Vargas Zúñiga, Daniela González Corrales, Celeste Ortega Monge, Pamela Ceciliano Porras, Mariana Cerdas Delgado, Jeison Montero Rivera

{"title":"Arsenic Trioxide: Pharmacological Applications","authors":"German Madrigal Redondo, M. F. Rojas Salas, Rolando Vargas Zúñiga, Daniela González Corrales, Celeste Ortega Monge, Pamela Ceciliano Porras, Mariana Cerdas Delgado, Jeison Montero Rivera","doi":"10.17533/udea.vitae.v30n1a349001","DOIUrl":null,"url":null,"abstract":"Background: Arsenic trioxide is a chemical compound that has been used as a treatment for various diseases. Despite being potentially toxic, this compound has been used as a therapy to treat Acute Myeloid Leukemia and is being investigated as a possible treatment for different types of cancer. Objectives: The present review aims to describe the use and studies reported in the literature of Arsenic Trioxide as a possible therapeutic agent for Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Chronic Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndrome, Hepatocellular Carcinoma, Lung Cancer, Neuroblastoma, Breast Cancer, Aplastic Hepatitis C, and HIV-1. Methods: A systematic review was conducted using databases (Elsevier, Google Scholar, PubMed) to compile documents published before December 2023. Results: Multiple pharmacological applications of arsenic trioxide have been reported to treat acute and chronic myeloid leukemia. Arsenic trioxide has been shown to inhibit angiogenesis, which helps treat multiple myeloma. Several studies have shown and suggested the effectiveness of arsenic trioxide as a treatment of hepatocellular carcinoma, lung cancer, neuroblastoma, prostate cancer, breast cancer, aplastic anemia, hepatitis C, and HIV-1.Conclusion: Despite potentially toxic effects, Arsenic compounds are therapeutic agents for multiple diseases, from syphilis to cancer. In recent years, more efficient ways have been investigated to deliver and find the specific dose to treat the disease, causing the fewest possible adverse effects.","PeriodicalId":51213,"journal":{"name":"Vitae","volume":"47 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vitae","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17533/udea.vitae.v30n1a349001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Arsenic trioxide is a chemical compound that has been used as a treatment for various diseases. Despite being potentially toxic, this compound has been used as a therapy to treat Acute Myeloid Leukemia and is being investigated as a possible treatment for different types of cancer. Objectives: The present review aims to describe the use and studies reported in the literature of Arsenic Trioxide as a possible therapeutic agent for Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Chronic Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndrome, Hepatocellular Carcinoma, Lung Cancer, Neuroblastoma, Breast Cancer, Aplastic Hepatitis C, and HIV-1. Methods: A systematic review was conducted using databases (Elsevier, Google Scholar, PubMed) to compile documents published before December 2023. Results: Multiple pharmacological applications of arsenic trioxide have been reported to treat acute and chronic myeloid leukemia. Arsenic trioxide has been shown to inhibit angiogenesis, which helps treat multiple myeloma. Several studies have shown and suggested the effectiveness of arsenic trioxide as a treatment of hepatocellular carcinoma, lung cancer, neuroblastoma, prostate cancer, breast cancer, aplastic anemia, hepatitis C, and HIV-1.Conclusion: Despite potentially toxic effects, Arsenic compounds are therapeutic agents for multiple diseases, from syphilis to cancer. In recent years, more efficient ways have been investigated to deliver and find the specific dose to treat the disease, causing the fewest possible adverse effects.

查看原文本刊更多论文

三氧化二砷:药理应用

背景:三氧化二砷是一种化合物，已被用于治疗多种疾病。尽管这种化合物有潜在的毒性，但它已被用作治疗急性髓性白血病的一种疗法，目前正在研究它是否可能治疗不同类型的癌症。目的:本综述旨在描述三氧化二砷作为急性髓性白血病、急性早幼粒细胞白血病、慢性髓性白血病、多发性骨髓瘤、骨髓增生异常综合征、肝细胞癌、肺癌、神经母细胞瘤、乳腺癌、再生性丙型肝炎和HIV-1的可能治疗剂的使用和文献报道。方法:采用数据库(Elsevier、Google Scholar、PubMed)对2023年12月前发表的文献进行系统评价。结果:三氧化二砷的多种药理应用已被报道用于治疗急性和慢性髓系白血病。三氧化二砷已被证明能抑制血管生成，这有助于治疗多发性骨髓瘤。几项研究表明，三氧化二砷可有效治疗肝细胞癌、肺癌、神经母细胞瘤、前列腺癌、乳腺癌、再生障碍性贫血、丙型肝炎和HIV-1。结论:尽管有潜在的毒性作用，砷化合物是多种疾病的治疗剂，从梅毒到癌症。近年来，已经研究了更有效的方法来提供和找到治疗疾病的特定剂量，造成尽可能少的副作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vitae PHARMACOLOGY & PHARMACY-

CiteScore

1.20

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： The journal VITAE is the four-monthly official publication of the School of Pharmaceutical and Food Sciences, and its mission is the diffusion of the scientific and investigative knowledge in the various fields of pharmaceutical and food research, and their related industries. The Journal VITAE is an open-access journal that publishes original and unpublished manuscripts, which are selected by the Editorial Board and then peer-reviewed. The editorial pages express the opinion of the Faculty regarding the various topics of interest. The judgments, opinions, and points of view expressed in the published articles are the responsibility of their authors.